Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.
Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.
REGENXBIO (NASDAQ:RGNX) announced three-year Phase II results from the ALTITUDE clinical trial evaluating investigational sura-vec for non-proliferative diabetic retinopathy (NPDR).
Mesoblast (NASDAQ:MESO) announced that the U.S. Food and Drug Administration (FDA) has approved the use of a new potency testing method for commercial batches of Ryoncil.
Satellos Bioscience (NASDAQ:MSLE) announced that it has received U.S. Food and Drug Administration (FDA) clearance to begin studying forazapadin in patients with facioscapulohumeral muscular dystrophy (FSHD).
Ligand Pharmaceuticals (NASDAQ:LGND) announced a financing agreement with AvenCell Therapeutics that could provide up to $47 million to support development of AvenCell’s cancer treatment pipeline.
IMUNON (NASDAQ:IMNN) presented Phase 2 survival results and Phase 3 enrollment updates for IMNN-001, its investigational therapy for advanced ovarian cancer.
Ainos (NASDAQ:AIMD) announced that it has entered into a VELDONA license agreement with BioPhoenix, establishing a conditional collaboration framework with a potential value of up to $10 million.
Acadia Pharmaceuticals (NASDAQ:ACAD) announced Phase 3-enabling topline results from the Phase 2 portion of its ongoing RADIANT clinical trial program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
Merck (NYSE:MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema (DME).
Eli Lilly (NYSE:LLY) received U.S. Food and Drug Administration approval on September 24, 2026, for Onswik, a once-weekly basal insulin treatment for adults with type 2 diabetes.
Biodesix (NASDAQ:BDSX) announced progress on two molecular residual disease (MRD) testing programs designed to detect circulating tumor DNA (ctDNA) in blood samples following cancer treatment.
